ESMO

Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program
Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program
Endpoints
Autolus Therapeutics
ESMO
CAR-T
diffuse large B-cell lymphoma
layoffs
Flag link:
Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst
Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst
Fierce Pharma
Gilead Sciences
Immunomedics
M&A
Trodelvy
ESMO
breast cancer
Flag link:
Esmo 2020 – can Alkermes succeed where Nektar failed?
Esmo 2020 – can Alkermes succeed where Nektar failed?
EP Vantage
Alkermes
ESMO
ALKS 4230
melanoma
Flag link:
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
BioSpace
AstraZeneca
clinical trials
Tagrisso
ESMO
non-small cell lung cancer
Flag link:
Esmo 2020 – More encouraging signs for checkpoint bispecifics
Esmo 2020 – More encouraging signs for checkpoint bispecifics
EP Vantage
ESMO
bispecifics
Macrogenics
Akeso
mesothelioma
AK104
MGD019
Flag link:
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
BioSpace
Mirati Therapeutics
sitravantinib
ESMO
urothelial cancer
Flag link:
#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap
#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap
Endpoints
Bristol-Myers Squibb
ESMO
Opdivo
esophageal cancer
Flag link:
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma
Libtayo
ESMO
Regeneron
Sanofi
non-small cell lung cancer
Flag link:
Amgen publishes, presents data on therapy with ‘undruggable’ target
Amgen publishes, presents data on therapy with ‘undruggable’ target
MedCity News
Amgen
sotorasib
ESMO
AMG 510
non-small cell lung cancer
Flag link:
Esmo 2020 – some backing for Beigene’s unusual combo approach
Esmo 2020 – some backing for Beigene’s unusual combo approach
EP Vantage
ESMO
BeiGene
urothelial cancer
Flag link:
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
Fierce Biotech
Roche
prostate cancer
ESMO
JNJ
Ipatasertib
Zytiga
Flag link:
ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More
ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More
BioSpace
ESMO
Merck
AstraZeneca
clinical tirals
Lynparza
ovarian cancer
Flag link:
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
Fierce Pharma
ESMO
Roche
Tecentriq
triple negative breast cancer
Merck
Keytruda
Flag link:
ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer
ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer
Fierce Pharma
Ibrance
Pfizer
Eli Lilly
Verzenio
breast cancer
ESMO
Flag link:
ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial
ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial
Fierce Pharma
ESMO
Pfizer
Merck KGaA
Bavencio
head and neck cancer
clinical trials
Flag link:
ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray
ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray
Fierce Pharma
ESMO
Novartis
breast cancer
Piqray
Faslodex
AstraZeneca
Flag link:
ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer
ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer
Fierce Pharma
Merck
ESMO
bladder cancer
metastatic bladder cancer
Keytruda
Flag link:
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
Endpoints
AstraZeneca
Tagrisso
non-small cell lung cancer
ESMO
Flag link:
Seattle Genetics stays step ahead of rivals with bladder cancer data
Seattle Genetics stays step ahead of rivals with bladder cancer data
BioPharma Dive
Seattle Genetics
Astellas
Padcev
bladder cancer
clinical trials
ESMO
Flag link:
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
Fierce Biotech
Alkermes
immuno-oncology
ESMO
ALKS 4230
Keytruda
Flag link:

Pages